TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33236208

Group type: EXPERIMENTAL
Intervention: Conventional TENS (high frequency and low intensity)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture-like TENS (low frequency and high intensity)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 60
Study: 36355202

Group type: EXPERIMENTAL
Intervention: Deep breathing (Group D)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 200
Study: 33389422

Group type: EXPERIMENTAL
Intervention: Corneal collagen cross‐linking treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Photorefractive keratectomy (control group)
Number of subjects: 54
Study: 32299845

Group type: EXPERIMENTAL
Intervention: Riociguat 0.5 mg to 2.5 mg orally three times daily (n=60)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (n=61)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 33845623

Group type: EXPERIMENTAL
Intervention: HA+ Zweymuller-type hip stem
Number of subjects: 51

Group type: COMPARATOR
Intervention: HA− Zweymuller-type hip stem
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: HA+ and HA− groups
Number of subjects: 51
Study: 34429138

Group type: EXPERIMENTAL
Intervention: Incentive spirometry (IS) performed before surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no preoperative spirometry)
Number of subjects: 80
Study: 33550242

Group type: EXPERIMENTAL
Intervention: Cognitive fusion-targeted biopsy
Number of subjects: 602

Group type: COMPARATOR
Intervention: Software-based fusion-targeted biopsy
Number of subjects: 602
Study: 34089122

Group type: EXPERIMENTAL
Intervention: tolvaptan
Number of subjects: 0
Study: 32130996

Group type: COMPARATOR
Intervention: Cancellous bone grafting (CBG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vascularized medial femoral condyle (MFC) autografts
Number of subjects: 20
Study: 35669656

Group type: EXPERIMENTAL
Intervention: Scalpel treatment (group B)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Lateral crypt block treatment (group A)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study: 32641220

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) for 16 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control diet for 16 weeks
Number of subjects: 20
Study: 32067873

Group type: EXPERIMENTAL
Intervention: Integrated collaborative care intervention
Number of subjects: 409
Study: 36319521

Group type: EXPERIMENTAL
Intervention: Virtual Reality application for 10 minutes
Number of subjects: 86

Group type: COMPARATOR
Intervention: Routine preoperative procedure
Number of subjects: 86
Study: 34333030

Group type: EXPERIMENTAL
Intervention: RBM20 variants
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: RBM20 heterozygotes
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: RBM20 expression in the left ventricle
Number of subjects: 793
Study: 32618539

Group type: EXPERIMENTAL
Intervention: Spanish version of the Internet Gaming Disorder Scale - Short Form (IGDS9-SF)
Number of subjects: 2173
Study: 35582124

Group type: EXPERIMENTAL
Intervention: BNT162b2/BNT162b2
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: BNT162b2/mRNA‐1273
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: mRNA‐1273/mRNA‐1273
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: mRNA‐1273/BNT162b2
Number of subjects: 390

Group type: COMPARATOR
Intervention: mRNA‐1273
Number of subjects: 390
Study: 32285486

Group type: EXPERIMENTAL
Intervention: Pressure injury prevention program
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1015
Study: 35902888

Group type: EXPERIMENTAL
Intervention: Substance Use Treatment and Recovery Team (START) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 32940731

Group type: EXPERIMENTAL
Intervention: Phase 3 Oxford UKR bearings
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bearings that did not overhang the tibia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Increasing BMI
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Increased area of overhang
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amount of medial overhang
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Distance between the bearing and tibial wall
Number of subjects: 40
Study: 35974292

Group type: EXPERIMENTAL
Intervention: AEON ™ Endostapler (Lexington Medical) LLES
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medtronic Endo GIA™ Tri‐Staple technology (MTS)
Number of subjects: 60
Study: 34281590

Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 35131124

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) plus HealthCall
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: NIAAA Clinician's Guide (CG) plus HealthCall
Number of subjects: 114

Group type: COMPARATOR
Intervention: CG-only
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: CG + HealthCall
Number of subjects: 114
Study: 33757520

Group type: EXPERIMENTAL
Intervention: BDP/FF/G (beclometasone dipropionate 100 µg, formoterol fumarate 6 µg, glycopyrronium 10 µg) via pressurised metered-dose inhaler, two puffs twice-daily for 24 weeks
Number of subjects: 708

Group type: COMPARATOR
Intervention: BUD/FF (budesonide 160 µg, formoterol fumarate 4.5 µg) via dry-powder inhaler, two puffs twice-daily for 24 weeks
Number of subjects: 708
Study: 32118385

Group type: EXPERIMENTAL
Intervention: Whey protein (WP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Leucine (LEU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 30
Study: 35152706

Group type: EXPERIMENTAL
Intervention: Pilates with elastic resistance (PAG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Pilates without elastic resistance (PG)
Number of subjects: 22
Study: 33825828

Group type: EXPERIMENTAL
Intervention: Topical timolol maleate solution, 0.5%, applied twice daily for 24 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo applied twice daily for 24 weeks
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Topical timolol maleate solution, 0.5%
Number of subjects: 69
Study: 32737862

Group type: EXPERIMENTAL
Intervention: Virtual game training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 33328284

Group type: EXPERIMENTAL
Intervention: Combo (50% basal rate reduction set at exercise onset with carbohydrate intake of 0.3 g/kg/h)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CHO-only (usual basal rate with carbohydrate intake of 0.3 g/kg/h)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: −90min50%BRR (50% basal rate reduction set 90 min pre-exercise)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: −90min50%BRR
Number of subjects: 15
Study: 33171431

Group type: EXPERIMENTAL
Intervention: Expressive writing intervention (4-day writing program adapted from Pennebaker and Beall, 1986)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Active control group (writing about untherapeutic topics)
Number of subjects: 154
Study: 35666856

Group type: EXPERIMENTAL
Intervention: Goat milk based infant formula (GMF)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Cow milk formula (CMF)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Breast fed (BF)
Number of subjects: 218
Study: 32895369

Group type: EXPERIMENTAL
Intervention: JNJ-61393215 (90 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JNJ-61393215 (dose-dependent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Alprazolam)
Number of subjects: 0
Study: 33603142

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 35765169

Group type: EXPERIMENTAL
Intervention: low‐intensity exercise with BFR during rest intervals (rBFR)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: low‐intensity exercise only (EO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: low‐intensity exercise with BFR during exercise (eBFR)
Number of subjects: 10
Study: 33813359

Group type: EXPERIMENTAL
Intervention: levodopa + donepezil (5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: levodopa + placebo
Number of subjects: 20
Study: 35168011

Group type: EXPERIMENTAL
Intervention: Values intervention
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: Growth intervention
Number of subjects: 895

Group type: COMPARATOR
Intervention: Study-skills control
Number of subjects: 895
Study: 33478571

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (penetration needling of Hand‐Yangming meridian, PNHM) for 16 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Observation period for 16 weeks followed by 16 weeks of compensation PNHM therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (PNHM)
Number of subjects: 60
Study: 32259412

Group type: EXPERIMENTAL
Intervention: Laser and chemical intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chemical intervention alone
Number of subjects: 24
Study: 35072287

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgotinib and GS-829845
Number of subjects: 0
Study: 34383006

Group type: EXPERIMENTAL
Intervention: Hypofractionated image-guided radiotherapy (IGRT) (60 Gy in 15 fractions)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (CFRT) (60 Gy in 30 fractions)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Hypofractionated IGRT
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (CFRT)
Number of subjects: 96
Study: 32863352

Group type: EXPERIMENTAL
Intervention: High-frequency CIA isolates (n = 19)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Low-frequency CIA isolates (n = 24)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: High-level HA isolates (n = 24)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Low-level HA isolates (n = 19)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: SCM group I
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: SCM group II
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: SCM allele type 10/type 11
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Presence of AMR phenotype/genotype
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Absence of AMR phenotype/genotype
Number of subjects: 117
Study: 34464438

Group type: EXPERIMENTAL
Intervention: CAD/CAM group with multistranded stainless steel wires
Number of subjects: 46

Group type: COMPARATOR
Intervention: Lab group with multistranded stainless steel wires
Number of subjects: 46

Group type: COMPARATOR
Intervention: Traditional group with stainless steel Ortho‐FlexTech wires
Number of subjects: 46
Study: 34511596

Group type: EXPERIMENTAL
Intervention: Fast wean arm (abrupt discontinuation of NCPAP from 6 cmH2O)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Slow wean arm (gradual wean of NCPAP at 4 cmH2O, weaning by 1 cmH2O per day)
Number of subjects: 66
Study: 35726837

Group type: EXPERIMENTAL
Intervention: HADS six weeks postpartum
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: HADS during follow-up
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: PCL-5 during follow-up
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: PUQE-24 severity measure
Number of subjects: 215
Study: 33763527

Group type: EXPERIMENTAL
Intervention: App-based blended-learning tool (intervention group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional teaching strategy (control group)
Number of subjects: 26
Study: 34962159

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) experience, 5-minute video using a head-mounted display
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) experience
Number of subjects: 40
Study: 34750707

Group type: EXPERIMENTAL
Intervention: 3D-display system
Number of subjects: 128

Group type: COMPARATOR
Intervention: 4K-display system
Number of subjects: 128
Study: 33023898

Group type: EXPERIMENTAL
Intervention: Metformin adherence (≥80%)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Metformin adherence
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Early adherence to metformin
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Planned strategies to promote adherence
Number of subjects: 868
Study: 36134465

Group type: EXPERIMENTAL
Intervention: Decaffeinated green coffee extract (DGCE) supplementation, 400 mg capsules, two capsules daily for 12 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo, two identical capsules daily for 12 weeks
Number of subjects: 44
Study: 616774622

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 140

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 140
Study: 35537641

Group type: EXPERIMENTAL
Intervention: Transaxillary thoracic outlet decompression (TA‐TOD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continued conservative treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Transaxillary thoracic outlet decompression (TA‐TOD) after conservative treatment
Number of subjects: 50
Study: 33675475

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) patients
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pre-dialysis CKD G3–5 patients
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with NAFLD
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with CKD
Number of subjects: 80
Study: 32043533

Group type: EXPERIMENTAL
Intervention: modified constraint‐induced movement therapy (mCIMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 30
Study: 34693613

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 1020

Group type: COMPARATOR
Intervention: No dapagliflozin
Number of subjects: 1020
Study: 33153937

Group type: EXPERIMENTAL
Intervention: PantoDict digital e‐learning program (Group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PantoDict digital e‐learning program + conventional instruction (Group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional instruction only (Group C)
Number of subjects: 36
Study: 32053556

Group type: EXPERIMENTAL
Intervention: Apraclonidine pre-SLT
Number of subjects: 35

Group type: COMPARATOR
Intervention: Diclofenac post-SLT
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo pre-SLT and post-SLT
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 35
Study: 35296912

Group type: EXPERIMENTAL
Intervention: TS-142 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TS-142 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TS-142 30 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33909409

Group type: EXPERIMENTAL
Intervention: SOLIS system (SOS-localization-based interaction screening)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SOLIS system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three other PPI detection methods (NanoBiT, SPR, pull-down assays)
Number of subjects: 0
Study: 34706819

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Combined intervention (OMT + respiratory training)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study: 35737553

Group type: EXPERIMENTAL
Intervention: Anodal tDCS delivered over the DLPFC at Fp3 site for 10 mins at 1.5 mA intensity
Number of subjects: 112

Group type: COMPARATOR
Intervention: Sham/control groups
Number of subjects: 112
Study: 33384265

Group type: EXPERIMENTAL
Intervention: Interactive powered toothbrushes (PT group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Manual toothbrushes (MT group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups (MT and PT)
Number of subjects: 36
Study: 616508090

Group type: EXPERIMENTAL
Intervention: Tablet condition (using a stylus and electronic tablet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Model building condition (using materials to build enclosures and figurines)
Number of subjects: 0
Study: 35985933

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 9167

Group type: EXPERIMENTAL
Intervention: Combination therapy (CT)
Number of subjects: 9167

Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 9167
Study: 34293959

Group type: EXPERIMENTAL
Intervention: Court-Type Traditional Thai Massage (CTTM)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Thai Hermit Exercise (THE)
Number of subjects: 46
Study: 35260419

Group type: EXPERIMENTAL
Intervention: imlifidase (0.25 mg/kg single dose)
Number of subjects: 15

Group type: COMPARATOR
Intervention: historical control cohort
Number of subjects: 15
Study: 33623054

Group type: EXPERIMENTAL
Intervention: Barefoot running
Number of subjects: 41

Group type: COMPARATOR
Intervention: Shod running
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups during the 15-min run
Number of subjects: 41
Study: 32797664

Group type: EXPERIMENTAL
Intervention: Faster R‐CNN with ResNet‐50
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Faster R‐CNN with VGG‐16
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group (normal group)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group (disc group)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group (injured group)
Number of subjects: 1500
Study: 34496096

Group type: EXPERIMENTAL
Intervention: Pomalidomide, bortezomib, and dexamethasone (PVd)
Number of subjects: 559
Study: 34254934

Group type: EXPERIMENTAL
Intervention: Home environmental assessment and modifications delivered by occupational therapists
Number of subjects: 1331

Group type: COMPARATOR
Intervention: Usual care (including falls prevention leaflet and routine care from general practitioner)
Number of subjects: 1331
Study: 32574478

Group type: EXPERIMENTAL
Intervention: Remote Microphone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CROS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bone Conduction Device on softband
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Contralateral Routing of Signal (CROS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 15

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 15
Study: 34775965

Group type: EXPERIMENTAL
Intervention: Medium flow regulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strong flow regulation
Number of subjects: 0
Study: 32688479

Group type: EXPERIMENTAL
Intervention: p[over ¯]_{c1}
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: p[over ¯]_{c2}
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: p[over ¯]_{c3}
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: p[over ¯]_{c4}
Number of subjects: 0
Study: 34252387

Group type: EXPERIMENTAL
Intervention: e‐health‐based screening strategy consisting of repetitive one‐minute photoplethysmographic (PPG) pulse wave assessments using a certified smartphone app (Preventicus Heartbeats), followed by a confirmatory 14‐day ECG patch (CardioMem CM 100 XT) in case of abnormal findings.
Number of subjects: 4400

Group type: COMPARATOR
Intervention: Routine symptom‐based screening.
Number of subjects: 4400
Study: 33023495

Group type: EXPERIMENTAL
Intervention: 10 ml 0.5% ropivacaine (Group A)
Number of subjects: 74

Group type: COMPARATOR
Intervention: 10 ml normal saline (Group B)
Number of subjects: 74
Study: 35430584

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) plus prednisone (P)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Continued ADT plus Abiraterone acetate (AA) plus prednisone (P)
Number of subjects: 68
Study: 34663559

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32842974

Group type: EXPERIMENTAL
Intervention: Hypofractionated thoracic radiotherapy plus durvalumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventionally fractionated thoracic radiotherapy plus durvalumab
Number of subjects: 0
Study: 33217861

Group type: EXPERIMENTAL
Intervention: Home-based therapy (HBT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual practice (UP)
Number of subjects: 42
Study: 35282662

Group type: EXPERIMENTAL
Intervention: ARNI (sacubitril/valsartan)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 131
Study: 32833484

Group type: EXPERIMENTAL
Intervention: Active exercise training condition
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait list symptom monitoring condition
Number of subjects: 90
Study: 32220069

Group type: EXPERIMENTAL
Intervention: Autologous transplant
Number of subjects: 1909

Group type: EXPERIMENTAL
Intervention: Allogeneic transplant
Number of subjects: 1909

Group type: EXPERIMENTAL
Intervention: Overall survival from relapse
Number of subjects: 1909

Group type: EXPERIMENTAL
Intervention: Cumulative risk of relapse
Number of subjects: 1909

Group type: EXPERIMENTAL
Intervention: Late relapse incidence
Number of subjects: 1909

Group type: EXPERIMENTAL
Intervention: Median time to late relapse
Number of subjects: 1909
Study: 33034672

Group type: EXPERIMENTAL
Intervention: Videofluoroscopy-based predictive model incorporating DVH parameters of swallowing organs at risk (SWOARs)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Videofluoroscopy-based predictive model incorporating DVH parameters of SWOARs
Number of subjects: 38
Study: 32314891

Group type: EXPERIMENTAL
Intervention: Digital guide plate (51 implants)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine implant restoration treatment (45 implants)
Number of subjects: 50
Study: 35544369

Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine (50 μg each)
Number of subjects: 4016

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4016
Study: 36201330

Group type: EXPERIMENTAL
Intervention: Peer-supported multicomponent exercise intervention (8 weeks)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 229